<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Eur J Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Eur. J. Neurol</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1468-1331</journal-id>
<journal-id journal-id-type="publisher-id">ENE</journal-id>
<journal-title-group>
<journal-title>European Journal of Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1351-5101</issn>
<issn pub-type="epub">1468-1331</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27222346</article-id>
<article-id pub-id-type="pmc">5089667</article-id>
<article-id pub-id-type="doi">10.1111/ene.13057</article-id>
<article-id pub-id-type="publisher-id">ENE13057</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Specific clinical signs and symptoms are predictive of clinical course in sporadic Creutzfeldt−Jakob disease</article-title>
<alt-title alt-title-type="left-running-head">E. Nakatani et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="ene13057-cr-0001">
<name>
<surname>Nakatani</surname>
<given-names>E.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="ene13057-cr-0002">
<name>
<surname>Kanatani</surname>
<given-names>Y.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0003">
<name>
<surname>Kaneda</surname>
<given-names>H.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0004">
<name>
<surname>Nagai</surname>
<given-names>Y.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="ene13057-curr-0001">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0005">
<name>
<surname>Teramukai</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0006">
<name>
<surname>Nishimura</surname>
<given-names>T.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0007">
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0008">
<name>
<surname>Kojima</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0009">
<name>
<surname>Kono</surname>
<given-names>H.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="ene13057-curr-0002">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0010">
<name>
<surname>Fukushima</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0011">
<name>
<surname>Kitamoto</surname>
<given-names>T.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ene13057-cr-0012">
<name>
<surname>Mizusawa</surname>
<given-names>H.</given-names>
</name>
<xref ref-type="aff" rid="ene13057-aff-0005">
<sup>5</sup>
</xref>
</contrib>
</contrib-group>
<aff id="ene13057-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Translational Research Informatics Center</named-content>
<institution>Foundation for Biomedical Research and Innovation</institution>
<named-content content-type="city">Kobe</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="ene13057-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Health Crisis Management</named-content>
<institution>National Institute of Public Health</institution>
<named-content content-type="city">Saitama</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="ene13057-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Biostatistics</named-content>
<named-content content-type="organisation-division">Graduate School of Medical Science</named-content>
<institution>Kyoto Prefectural University of Medicine</institution>
<named-content content-type="city">Kyoto</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="ene13057-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Neurological Science</named-content>
<institution>Tohoku University Graduate School of Medicine</institution>
<named-content content-type="city">Sendai</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="ene13057-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>National Center of Neurology and Psychiatry</institution>
<named-content content-type="city">Tokyo</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="ene13057-curr-0001"><label><sup>6</sup></label>Present address: <institution>Center for Clinical Research Kobe University Hospital</institution><named-content content-type="city">Kobe</named-content><country country="JP">Japan</country></aff>
<aff id="ene13057-curr-0002"><label><sup>7</sup></label>Present address: <institution>ONO Pharmaceutical Co., Ltd.</institution><named-content content-type="city">Osaka</named-content><country country="JP">Japan</country></aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>Correspondence: Y. Kanatani, 2‐3‐6 Minami, Wako, Saitama 351‐0197, Japan (tel.: +81 48 458 6178; fax: +81 468 7983; e‐mail: <email>ykanatani@niph.go.jp</email>).</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2016</year>
</pub-date>
<volume>23</volume>
<issue>9</issue>
<issue-id pub-id-type="doi">10.1111/ene.2016.23.issue-9</issue-id>
<fpage>1455</fpage>
<lpage>1462</lpage>
<history>
<date date-type="received">
<day>12</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>4</month>
<year>2016</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> European Journal of Neurology &#x000a9; 2016 European Academy of Neurology <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2016 The Authors. <italic>European Journal of Neurology</italic> published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</copyright-statement>
<license license-type="creativeCommonsBy-nc-nd">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution‐NonCommercial‐NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:ENE-23-1455.pdf" xlink:type="simple"></self-uri>
<abstract id="ene13057-abs-0001">
<sec id="ene13057-sec-0001">
<title>Background and purpose</title>
<p>Akinetic mutism is thought to be an appropriate therapeutic end‐point in patients with sporadic Creutzfeldt−Jakob disease (<styled-content style="fixed-case">sCJD</styled-content>). However, prognostic factors for akinetic mutism are unclear and clinical signs or symptoms that precede this condition have not been defined. The goal of this study was to identify prognostic factors for akinetic mutism and to clarify the order of clinical sign and symptom development prior to its onset.</p>
</sec>
<sec id="ene13057-sec-0002">
<title>Methods</title>
<p>The cumulative incidence of akinetic mutism and other clinical signs and symptoms was estimated based on Japanese <styled-content style="fixed-case">CJD</styled-content> surveillance data (455 cases) collected from 2003 to 2008. A proportional hazards model was used to identify prognostic factors for the time to onset of akinetic mutism and other clinical signs and symptoms.</p>
</sec>
<sec id="ene13057-sec-0003">
<title>Results</title>
<p>Periodic synchronous discharges on electroencephalography were present in the majority of cases (93.5%). The presence of psychiatric symptoms or cerebellar disturbance at <styled-content style="fixed-case">sCJD</styled-content> diagnosis was associated with the development of akinetic mutism [hazard ratio (<styled-content style="fixed-case">HR</styled-content>) 1.50, 95% confidence interval (<styled-content style="fixed-case">CI</styled-content>) 1.14–1.99, and <styled-content style="fixed-case">HR</styled-content> 2.15, 95% <styled-content style="fixed-case">CI</styled-content>1.61–2.87, respectively]. The clinical course from cerebellar disturbance to myoclonus or akinetic mutism was classified into three types: (i) direct path, (ii) path via pyramidal or extrapyramidal dysfunction and (iii) path via psychiatric symptoms or visual disturbance.</p>
</sec>
<sec id="ene13057-sec-0004">
<title>Conclusions</title>
<p>The presence of psychiatric symptoms or cerebellar disturbance increased the risk of akinetic mutism of <styled-content style="fixed-case">sCJD</styled-content> cases with probable <styled-content style="fixed-case">MM</styled-content>/<styled-content style="fixed-case">MV</styled-content> subtypes. Also, there appear to be sequential associations in the development of certain clinical signs and symptoms of this disease.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="ene13057-kwd-0001">predictive factor</kwd>
<kwd id="ene13057-kwd-0002">prognosis</kwd>
<kwd id="ene13057-kwd-0003">signs and symptoms</kwd>
<kwd id="ene13057-kwd-0004">sporadic Creutzfeldt−Jakob disease</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Health and Labour Sciences Research from the MHLW</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>Research on Measures for Intractable Disease (Prion Disease)</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="8"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>ene13057</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>September 2016</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.6 mode:remove_FC converted:01.11.2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="ene13057-sec-0005">
<title>Introduction</title>
<p>Creutzfeldt−Jakob disease (CJD) is a lethal disorder that is caused by abnormal prion protein (PrP). CJD has a long incubation period but rapidly progresses to serious disability and death. It is categorized into four subtypes: sporadic, genetic/familial, iatrogenic and variant CJD. Sporadic CJD (sCJD) is the most common form of CJD, accounting for 85%–95% of all cases, and has unknown epidemiological factors <xref ref-type="ref" rid="ene13057-bib-0001">1</xref>, <xref ref-type="ref" rid="ene13057-bib-0002">2</xref>, <xref ref-type="ref" rid="ene13057-bib-0003">3</xref>. The median disease duration is approximately 5 months <xref ref-type="ref" rid="ene13057-bib-0004">4</xref>. Because both the genotype at codon 129 of the PrP gene (MM, MV or VV) and PrP type <xref ref-type="ref" rid="ene13057-bib-0002">2</xref>, <xref ref-type="ref" rid="ene13057-bib-0003">3</xref> act as determinants of the disease phenotype, patients with sCJD can be classified into six groups: MM1, MM2, MV1, MV2, VV1 and VV2 <xref ref-type="ref" rid="ene13057-bib-0005">5</xref>, <xref ref-type="ref" rid="ene13057-bib-0006">6</xref>.</p>
<p>A longer survival of sCJD patients has been associated with female gender, younger age of onset, codon 129 heterozygosity, PrP type 2a, the presence of pseudo‐periodic sharp‐wave complexes on electroencephalography (EEG) and the presence of 14‐3‐3 proteins in the cerebrospinal fluid (CSF) <xref ref-type="ref" rid="ene13057-bib-0004">4</xref>, <xref ref-type="ref" rid="ene13057-bib-0007">7</xref>, <xref ref-type="ref" rid="ene13057-bib-0008">8</xref>. Several other studies have examined the likelihood of longer survival from the perspectives of symptoms alone <xref ref-type="ref" rid="ene13057-bib-0009">9</xref> or of relationships between molecular subtype and phenotype <xref ref-type="ref" rid="ene13057-bib-0010">10</xref>. However, factors that may predict the time from diagnosis to onset of akinetic mutism or other clinical signs and symptoms are unknown.</p>
<p>Several studies have suggested that akinetic mutism is a more suitable end‐point than death for evaluating the efficacy of new therapeutic agents <xref ref-type="ref" rid="ene13057-bib-0011">11</xref>, <xref ref-type="ref" rid="ene13057-bib-0012">12</xref>, <xref ref-type="ref" rid="ene13057-bib-0013">13</xref>, <xref ref-type="ref" rid="ene13057-bib-0014">14</xref>. Accordingly, the current study aimed to identify prognostic factors for akinetic mutism and to clarify the order of appearance of clinical signs and symptoms prior to its onset.</p>
</sec>
<sec id="ene13057-sec-0006">
<title>Methods</title>
<sec id="ene13057-sec-0007">
<title>Data</title>
<p>This study analyzed data from the annual reports of clinical research submitted to the Specified Disease Treatment Research Program of the Japanese Ministry of Health, Labour and Welfare (MHLW) from 2003 to 2008 <xref ref-type="ref" rid="ene13057-bib-0015">15</xref>, <xref ref-type="ref" rid="ene13057-bib-0016">16</xref>. A longitudinal dataset was prepared based on cross‐sectional data obtained from the annual reports.</p>
</sec>
<sec id="ene13057-sec-0008">
<title>Variables</title>
<p>Data were collected on baseline characteristics at diagnosis [gender, time from onset to diagnosis, age at diagnosis, and presence of hyperintense signal on magnetic resonance imaging (MRI) or wave slowing or periodic synchronous discharges (PSDs) on EEG] and dates of diagnosis and onset of clinical signs or symptoms. Clinical signs and symptoms assessed were akinetic mutism, psychiatric symptoms (depression, fretfulness, anxiety, autism, apathy, insomnia, obsession, derangement, excitement, abnormal emotion, character change, abnormal behavior or memory disorder), visual disturbance, cerebellar disturbance, pyramidal dysfunction (excluding progressive dementia or impaired consciousness), extrapyramidal dysfunction and myoclonus. The case report form of this surveillance was created by the experts of medical societies for CJD; it was approved by the expert committee of the MHLW. The case report form was submitted by physicians who diagnosed the CJD patients and was reviewed by an advisory board of neurology experts in each prefecture.</p>
<p>Times to onset of akinetic mutism and other signs and symptoms were measured from sCJD diagnosis. Importantly, sCJD diagnosis rather than initial onset was used as the starting point in order to examine the temporal window for potential treatment before akinetic mutism onset.</p>
</sec>
<sec id="ene13057-sec-0009">
<title>Sporadic CJD diagnosis</title>
<p>The diagnosis of sCJD had already been performed by the Japanese Surveillance Committee based primarily on the 1998 World Health Organization diagnostic criteria. ‘Probable’ sCJD was diagnosed in patients with progressive dementia in the absence of an alternative diagnosis based on routine examination; at least two of the four clinical signs or symptoms (myoclonus, visual or cerebellar disturbance, pyramidal or extrapyramidal dysfunction, or akinetic mutism); a typical EEG with generalized triphasic periodic complexes at approximately 1/s, regardless of the duration of the disease; or a positive 14‐3‐3 assay of the CSF and death in under 2 years. ‘Definite’ sCJD cases were defined as those with a confirmed pathological diagnosis at autopsy, the presence of PrP protein based on immunocytochemistry or western blotting, or the presence of scrapie‐associated fibrils.</p>
</sec>
<sec id="ene13057-sec-0010">
<title>Statistical analysis</title>
<p>‘Definite’ and ‘probable’ sCJD cases were included in the analysis. Only cases without akinetic mutism at diagnosis were included, because the presence of akinetic mutism precluded the onset of other clinical signs and symptoms. Categorical and continuous data are presented as number of patients (percentage) and mean ± standard deviation, respectively. The cumulative incidence of akinetic mutism was estimated using the Kaplan–Meier method. The Cox proportional hazards model was used to identify prognostic factors for the time from sCJD diagnosis to akinetic mutism onset. The cumulative incidences of other clinical signs and symptoms were calculated adjusting for akinetic mutism as a competing risk <xref ref-type="ref" rid="ene13057-bib-0017">17</xref>. The Fine−Gray proportional hazards model <xref ref-type="ref" rid="ene13057-bib-0018">18</xref>, adjusted for akinetic mutism, was used to evaluate relationships between clinical signs and symptoms present at diagnosis and the time to development of other signs or symptoms. Candidate prognostic factors were selected based on <italic>P</italic> &lt; 0.05 in a Wald test and the number of cases in univariate analyses. Prognostic factors were selected using the backward selection method at <italic>P</italic> &lt; 0.05 in multivariate analyses. Hazard ratios (HRs) and 95% confidence intervals (CIs), using the Wald test, were calculated. The median time to onset of each clinical sign or symptom was calculated. Analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) and R version 3.0.2 (R Foundation, Vienna, Austria) with the competing risks (cmprsk) library.</p>
</sec>
<sec id="ene13057-sec-0011">
<title>Ethics</title>
<p>This study conforms to the ethical guidelines for epidemiological research issued by the MHLW and the Ministry of Education, Culture, Sports, Science and Technology. The ethics committee of the National Institute of Public Health approved this study (No. 218; 10 June 2010). All patients or their proxies gave written informed consent for registration in the Specified Disease Treatment Research Program, and their information was sent to their respective prefectural governors. Following submission of informed consent forms and the approval of a review committee, each patient's information was anonymized and entered into the MHLW database. The anonymized data were provided to us for analysis (Notification of Health Service Bureau, MHLW; No. 0708‐1; 8 July 2010).</p>
</sec>
</sec>
<sec id="ene13057-sec-0012">
<title>Results</title>
<sec id="ene13057-sec-0013">
<title>Demographic data</title>
<p>A total of 717 sCJD case reports (‘definite’ 52, ‘probable’ 665) submitted between 2003 and 2008 were included in the analysis. After excluding cases with akinetic mutism at sCJD diagnosis, the dataset comprised 455 cases (Table <xref ref-type="table-wrap" rid="ene13057-tbl-0001">1</xref>). Genetic testing for genotype at codon 129 of the PrP gene was performed in 108 cases. The majority of cases that included EEG data showed PSDs (93.5%). The number of females was approximately 1.57 times higher than the number of males. The median period from disease onset to diagnosis was 1.2 months (range 0.0–12.5), and the median age at diagnosis was 70 years (range 39–95).</p>
<table-wrap id="ene13057-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Baseline characteristics of sCJD patients</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Variable at diagnosis</th>
<th align="char" colspan="1" rowspan="1" valign="top">
<italic>n</italic> = 455</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">sCJD diagnosis (definite:probable)</td>
<td align="char" char=" " colspan="1" rowspan="1">38:417</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male gender</td>
<td align="char" char=" " colspan="1" rowspan="1">177 (38.9%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Time from onset to diagnosis (months)</td>
<td align="char" char=" " colspan="1" rowspan="1">2.9 ± 2.1 (<italic>n</italic> = 437)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Age at diagnosis (years)</td>
<td align="char" char=" " colspan="1" rowspan="1">68.9 ± 9.1 (<italic>n</italic> = 433)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">31–40</td>
<td align="char" char=" " colspan="1" rowspan="1">3 (0.7%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">41–50</td>
<td align="char" char=" " colspan="1" rowspan="1">12 (2.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">51–60</td>
<td align="char" char=" " colspan="1" rowspan="1">60 (13.9%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">61–70</td>
<td align="char" char=" " colspan="1" rowspan="1">157 (36.3%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">71–80</td>
<td align="char" char=" " colspan="1" rowspan="1">168 (38.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">81–90</td>
<td align="char" char=" " colspan="1" rowspan="1">31 (7.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">91–100</td>
<td align="char" char=" " colspan="1" rowspan="1">2 (0.5%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Codon 129 genotype (MM:MV, total percentage of 455 cases)</td>
<td align="char" char=" " colspan="1" rowspan="1">98:10 (23.7%)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">EEG and MRI findings</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">PSD on EEG</td>
<td align="char" char=" " colspan="1" rowspan="1">417/446 (93.5%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Wave slowing on EEG</td>
<td align="char" char=" " colspan="1" rowspan="1">367/407 (90.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Hyperintensity on MRI</td>
<td align="char" char=" " colspan="1" rowspan="1">377/402 (93.8%)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Cerebrospinal fluid analysis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Increase in proteins</td>
<td align="char" char=" " colspan="1" rowspan="1">107/348 (30.7%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Increase in cells</td>
<td align="char" char=" " colspan="1" rowspan="1">17/335 (5.1%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Increase in NSE</td>
<td align="char" char=" " colspan="1" rowspan="1">132/156 (84.6%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Increase in 14‐3‐3 proteins</td>
<td align="char" char=" " colspan="1" rowspan="1">96/118 (81.4%)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Clinical signs and symptoms</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Psychiatric symptoms</td>
<td align="char" char=" " colspan="1" rowspan="1">195/387 (50.4%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Visual disturbance</td>
<td align="char" char=" " colspan="1" rowspan="1">138/308 (44.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Cerebellar disturbance</td>
<td align="char" char=" " colspan="1" rowspan="1">183/360 (50.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Pyramidal dysfunction</td>
<td align="char" char=" " colspan="1" rowspan="1">134/418 (32.1%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Extrapyramidal dysfunction</td>
<td align="char" char=" " colspan="1" rowspan="1">116/397 (29.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Myoclonus</td>
<td align="char" char=" " colspan="1" rowspan="1">127/443 (28.7%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="ene13057-note-0001">
<p>EEG, electroencephalography; MRI, magnetic resonance imaging; NSE, neuron‐specific enolase; PSD, periodic synchronous discharge; sCJD, sporadic Creutzfeldt−Jakob disease. The denominator for calculating the proportion on cerebrospinal fluid analysis was the total of normal and increase.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="ene13057-sec-0014">
<title>Incidence of clinical signs or symptoms prior to onset of akinetic mutism</title>
<p>The cumulative incidences of clinical signs and symptoms are shown in Fig. <xref ref-type="fig" rid="ene13057-fig-0001">1</xref>. The cumulative incidence (95% CI) of akinetic mutism at 3, 6 and 12 months after diagnosis of sCJD was 67.8% (62.7%–72.9%), 78.6% (73.3%–82.8%) and 85.7% (80.7%–89.4%), respectively (Fig. <xref ref-type="fig" rid="ene13057-fig-0001">1</xref>a). The median times to onset of akinetic mutism, myoclonus, pyramidal dysfunction, extrapyramidal dysfunction, psychiatric symptoms, cerebellar disturbance and visual disturbance were 1.51, 0.56, 0.56, 0.86, 0.36, 0.53 and 2.17 months, respectively (Fig. <xref ref-type="fig" rid="ene13057-fig-0001">1</xref>).</p>
<fig fig-type="Figure" id="ene13057-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Cumulative incidences of clinical signs and symptoms. Cumulative incidence plots of (a) akinetic mutism; (b) myoclonus, pyramidal dysfunction and extrapyramidal dysfunction; and (c) psychiatric symptoms, cerebellar disturbance and visual disturbance.</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="ENE-23-1455-g001"></graphic>
</fig>
</sec>
<sec id="ene13057-sec-0015">
<title>Relationships between clinical signs and symptoms and time to akinetic mutism onset</title>
<p>Significant factors identified by a univariate Cox regression analysis were considered candidate prognostic factors for akinetic mutism (Table <xref ref-type="table-wrap" rid="ene13057-tbl-0002">2</xref>). A multivariate Cox regression analysis demonstrated that the presence of psychiatric symptoms or cerebellar disturbance at diagnosis was predictive of akinetic mutism (HR 1.50, 95% CI 1.14–1.99, <italic>P</italic> = 0.004, and HR 2.15, 95% CI 1.61–2.87, <italic>P</italic> &lt; 0.001, respectively; Table <xref ref-type="table-wrap" rid="ene13057-tbl-0002">2</xref>). The stratified cumulative incidence of akinetic mutism is shown in Fig. <xref ref-type="fig" rid="ene13057-fig-0002">2</xref>. The median times to akinetic mutism onset in patients with psychiatric symptoms and cerebellar disturbance, cerebellar disturbance only, psychiatric symptoms only, and neither condition were 0.99, 1.51, 1.88 and 2.93 months, respectively (Fig. <xref ref-type="fig" rid="ene13057-fig-0002">2</xref>).</p>
<table-wrap id="ene13057-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>Univariate and multivariate regression analyses of time to akinetic mutism onset</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top">Variable at diagnosis (reference or unit)</th>
<th align="char" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Univariate regression</th>
<th align="char" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Multivariate regression</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="char" colspan="1" rowspan="1" valign="top">HR</th>
<th align="char" colspan="1" rowspan="1" valign="top">95% CI</th>
<th align="char" colspan="1" rowspan="1" valign="top">
<italic>P</italic>
</th>
<th align="char" colspan="1" rowspan="1" valign="top">HR</th>
<th align="char" colspan="1" rowspan="1" valign="top">95% CI</th>
<th align="char" colspan="1" rowspan="1" valign="top">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Gender: male (female)</td>
<td align="char" char="." colspan="1" rowspan="1">0.95</td>
<td align="char" char="–" colspan="1" rowspan="1">0.75–1.20</td>
<td align="char" char="." colspan="1" rowspan="1">0.676</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Time from onset to diagnosis (1 month)</td>
<td align="char" char="." colspan="1" rowspan="1">1.04</td>
<td align="char" char="–" colspan="1" rowspan="1">0.91–1.02</td>
<td align="char" char="." colspan="1" rowspan="1">0.169</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Age at diagnosis (1 year)</td>
<td align="char" char="." colspan="1" rowspan="1">0.99</td>
<td align="char" char="–" colspan="1" rowspan="1">0.98–1.01</td>
<td align="char" char="." colspan="1" rowspan="1">0.425</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Codon 129 genotype: MM (MV)</td>
<td align="char" char="." colspan="1" rowspan="1">3.45</td>
<td align="char" char="–" colspan="1" rowspan="1">1.39–9.09</td>
<td align="char" char="." colspan="1" rowspan="1">0.007</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1">EEG and MRI findings</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">PSD on EEG</td>
<td align="char" char="." colspan="1" rowspan="1">1.77</td>
<td align="char" char="–" colspan="1" rowspan="1">1.07–2.93</td>
<td align="char" char="." colspan="1" rowspan="1">0.028</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Wave slowing on EEG</td>
<td align="char" char="." colspan="1" rowspan="1">0.69</td>
<td align="char" char="–" colspan="1" rowspan="1">0.42–1.11</td>
<td align="char" char="." colspan="1" rowspan="1">0.126</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Hyperintensity on MRI</td>
<td align="char" char="." colspan="1" rowspan="1">1.10</td>
<td align="char" char="–" colspan="1" rowspan="1">0.67–1.81</td>
<td align="char" char="." colspan="1" rowspan="1">0.700</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1">Cerebrospinal fluid analysis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Increase in proteins</td>
<td align="char" char="." colspan="1" rowspan="1">1.29</td>
<td align="char" char="–" colspan="1" rowspan="1">0.98–1.70</td>
<td align="char" char="." colspan="1" rowspan="1">0.067</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Increase in cells</td>
<td align="char" char="." colspan="1" rowspan="1">1.88</td>
<td align="char" char="–" colspan="1" rowspan="1">1.13–3.14</td>
<td align="char" char="." colspan="1" rowspan="1">0.016</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Increase in NSE</td>
<td align="char" char="." colspan="1" rowspan="1">2.11</td>
<td align="char" char="–" colspan="1" rowspan="1">1.21–3.66</td>
<td align="char" char="." colspan="1" rowspan="1">0.008</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Increase in 14‐3‐3 proteins</td>
<td align="char" char="." colspan="1" rowspan="1">2.69</td>
<td align="char" char="–" colspan="1" rowspan="1">1.45–4.97</td>
<td align="char" char="." colspan="1" rowspan="1">0.002</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1">Clinical signs and symptoms</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Myoclonus</td>
<td align="char" char="." colspan="1" rowspan="1">1.57</td>
<td align="char" char="–" colspan="1" rowspan="1">1.20–2.06</td>
<td align="char" char="." colspan="1" rowspan="1">0.001</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Pyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">1.24</td>
<td align="char" char="–" colspan="1" rowspan="1">0.95–1.60</td>
<td align="char" char="." colspan="1" rowspan="1">0.115</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Extrapyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">1.27</td>
<td align="char" char="–" colspan="1" rowspan="1">0.97–1.66</td>
<td align="char" char="." colspan="1" rowspan="1">0.085</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Psychiatric symptoms</td>
<td align="char" char="." colspan="1" rowspan="1">1.78</td>
<td align="char" char="–" colspan="1" rowspan="1">1.38–2.29</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
<td align="char" char="." colspan="1" rowspan="1">1.50</td>
<td align="char" char="–" colspan="1" rowspan="1">1.14–1.99</td>
<td align="char" char="." colspan="1" rowspan="1">0.004</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Cerebellar disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">2.30</td>
<td align="char" char="–" colspan="1" rowspan="1">1.75–3.01</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
<td align="char" char="." colspan="1" rowspan="1">2.15</td>
<td align="char" char="–" colspan="1" rowspan="1">1.61–2.87</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Visual disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.83</td>
<td align="char" char="–" colspan="1" rowspan="1">1.36–2.47</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="ene13057-note-0002">
<p>CI, confidence interval; HR, hazard ratio; other abbreviations as in Table <xref ref-type="table-wrap" rid="ene13057-tbl-0001">1</xref>. The reference for estimating HRs for clinical signs and symptoms and EEG and MRI findings is absence against presence. The reference for estimating HRs for cerebrospinal fluid analysis is normal against increase.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<fig fig-type="Figure" id="ene13057-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>Stratified cumulative incidence of akinetic mutism based on prognostic factors. Stratified cumulative incidence of akinetic mutism based on the presence of cerebellar disturbance and/or psychiatric symptoms at diagnosis.</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="ENE-23-1455-g002"></graphic>
</fig>
</sec>
<sec id="ene13057-sec-0016">
<title>Relationships between clinical signs and symptoms</title>
<p>The results of a Fine−Gray regression analysis of clinical signs and symptoms are shown in Table <xref ref-type="table-wrap" rid="ene13057-tbl-0003">3</xref>. Notably, the presence of cerebellar disturbance at diagnosis was predictive of subsequent development of myoclonus, pyramidal and extrapyramidal dysfunction, and visual disturbance. A schematic description of the order of development of signs and symptoms is presented in Fig. <xref ref-type="fig" rid="ene13057-fig-0003">3</xref>. Clinical courses from cerebellar disturbance to myoclonus or akinetic mutism were classified into three types: (i) direct path (Fig. <xref ref-type="fig" rid="ene13057-fig-0003">3</xref>, center), (ii) path via pyramidal or extrapyramidal dysfunction (Fig. <xref ref-type="fig" rid="ene13057-fig-0003">3</xref>, left) and (iii) path via psychiatric symptoms or visual disturbance (Fig. <xref ref-type="fig" rid="ene13057-fig-0003">3</xref>, right).</p>
<table-wrap id="ene13057-tbl-0003" orientation="portrait" position="float" xml:lang="en">
<label>Table 3</label>
<caption>
<p>Univariate and multivariate regression analyses of time to onset of other clinical signs and symptoms</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top">Clinical sign or symptom as outcome</th>
<th align="left" colspan="1" rowspan="2" valign="top">Clinical signs and symptoms at diagnosis</th>
<th align="char" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Univariate regression</th>
<th align="char" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Multivariate regression</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="char" colspan="1" rowspan="1" valign="top">HR</th>
<th align="char" colspan="1" rowspan="1" valign="top">95% CI</th>
<th align="char" colspan="1" rowspan="1" valign="top">
<italic>P</italic>
</th>
<th align="char" colspan="1" rowspan="1" valign="top">HR</th>
<th align="char" colspan="1" rowspan="1" valign="top">95% CI</th>
<th align="char" colspan="1" rowspan="1" valign="top">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="5">Myoclonus</td>
<td align="left" colspan="1" rowspan="1">Pyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">1.56</td>
<td align="char" char="–" colspan="1" rowspan="1">1.24–1.97</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
<td align="char" char="." colspan="1" rowspan="1">1.67</td>
<td align="char" char="–" colspan="1" rowspan="1">1.25–2.23</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Extrapyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">1.52</td>
<td align="char" char="–" colspan="1" rowspan="1">1.18–1.94</td>
<td align="char" char="." colspan="1" rowspan="1">0.001</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychiatric symptoms</td>
<td align="char" char="." colspan="1" rowspan="1">1.36</td>
<td align="char" char="–" colspan="1" rowspan="1">1.11–1.67</td>
<td align="char" char="." colspan="1" rowspan="1">0.003</td>
<td align="char" char="." colspan="1" rowspan="1">1.54</td>
<td align="char" char="–" colspan="1" rowspan="1">1.20–1.97</td>
<td align="char" char="." colspan="1" rowspan="1">0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cerebellar disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.98</td>
<td align="char" char="–" colspan="1" rowspan="1">1.56–2.52</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
<td align="char" char="." colspan="1" rowspan="1">1.45</td>
<td align="char" char="–" colspan="1" rowspan="1">1.08–1.96</td>
<td align="char" char="." colspan="1" rowspan="1">0.013</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Visual disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.65</td>
<td align="char" char="–" colspan="1" rowspan="1">1.31–2.08</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
<td align="char" char="." colspan="1" rowspan="1">1.40</td>
<td align="char" char="–" colspan="1" rowspan="1">1.08–1.81</td>
<td align="char" char="." colspan="1" rowspan="1">0.011</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="5">Pyramidal dysfunction</td>
<td align="left" colspan="1" rowspan="1">Myoclonus</td>
<td align="char" char="." colspan="1" rowspan="1">1.64</td>
<td align="char" char="–" colspan="1" rowspan="1">1.27–2.11</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
<td align="char" char="." colspan="1" rowspan="1">1.59</td>
<td align="char" char="–" colspan="1" rowspan="1">1.17–2.15</td>
<td align="char" char="." colspan="1" rowspan="1">0.003</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Extrapyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">3.66</td>
<td align="char" char="–" colspan="1" rowspan="1">2.43–5.50</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychiatric symptoms</td>
<td align="char" char="." colspan="1" rowspan="1">1.14</td>
<td align="char" char="–" colspan="1" rowspan="1">0.92–1.41</td>
<td align="char" char="." colspan="1" rowspan="1">0.250</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cerebellar disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.55</td>
<td align="char" char="–" colspan="1" rowspan="1">1.23–1.96</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
<td align="char" char="." colspan="1" rowspan="1">1.40</td>
<td align="char" char="–" colspan="1" rowspan="1">1.11–1.78</td>
<td align="char" char="." colspan="1" rowspan="1">0.005</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Visual disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.10</td>
<td align="char" char="–" colspan="1" rowspan="1">0.85–1.41</td>
<td align="char" char="." colspan="1" rowspan="1">0.470</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="5">Extrapyramidal dysfunction</td>
<td align="left" colspan="1" rowspan="1">Myoclonus</td>
<td align="char" char="." colspan="1" rowspan="1">1.43</td>
<td align="char" char="–" colspan="1" rowspan="1">1.09–1.87</td>
<td align="char" char="." colspan="1" rowspan="1">0.009</td>
<td align="char" char="." colspan="1" rowspan="1">1.59</td>
<td align="char" char="–" colspan="1" rowspan="1">1.17–2.18</td>
<td align="char" char="." colspan="1" rowspan="1">0.003</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">1.02</td>
<td align="char" char="–" colspan="1" rowspan="1">0.79–1.32</td>
<td align="char" char="." colspan="1" rowspan="1">0.860</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychiatric symptoms</td>
<td align="char" char="." colspan="1" rowspan="1">1.09</td>
<td align="char" char="–" colspan="1" rowspan="1">0.88–1.36</td>
<td align="char" char="." colspan="1" rowspan="1">0.430</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cerebellar disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.50</td>
<td align="char" char="–" colspan="1" rowspan="1">1.19–1.88</td>
<td align="char" char="." colspan="1" rowspan="1">0.001</td>
<td align="char" char="." colspan="1" rowspan="1">1.36</td>
<td align="char" char="–" colspan="1" rowspan="1">1.08–1.71</td>
<td align="char" char="." colspan="1" rowspan="1">0.009</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Visual disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.05</td>
<td align="char" char="–" colspan="1" rowspan="1">0.82–1.34</td>
<td align="char" char="." colspan="1" rowspan="1">0.720</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="5">Psychiatric symptoms</td>
<td align="left" colspan="1" rowspan="1">Myoclonus</td>
<td align="char" char="." colspan="1" rowspan="1">0.97</td>
<td align="char" char="–" colspan="1" rowspan="1">0.77–1.22</td>
<td align="char" char="." colspan="1" rowspan="1">0.770</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">1.07</td>
<td align="char" char="–" colspan="1" rowspan="1">0.86–1.33</td>
<td align="char" char="." colspan="1" rowspan="1">0.550</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Extrapyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">1.03</td>
<td align="char" char="–" colspan="1" rowspan="1">0.82–1.29</td>
<td align="char" char="." colspan="1" rowspan="1">0.820</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cerebellar disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.04</td>
<td align="char" char="–" colspan="1" rowspan="1">0.84–1.28</td>
<td align="char" char="." colspan="1" rowspan="1">0.720</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Visual disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.40</td>
<td align="char" char="–" colspan="1" rowspan="1">1.11–1.77</td>
<td align="char" char="." colspan="1" rowspan="1">0.005</td>
<td align="char" char="." colspan="1" rowspan="1">1.40</td>
<td align="char" char="–" colspan="1" rowspan="1">1.11–1.77</td>
<td align="char" char="." colspan="1" rowspan="1">0.005</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="5">Cerebellar disturbance</td>
<td align="left" colspan="1" rowspan="1">Myoclonus</td>
<td align="char" char="." colspan="1" rowspan="1">1.04</td>
<td align="char" char="–" colspan="1" rowspan="1">0.84–1.28</td>
<td align="char" char="." colspan="1" rowspan="1">0.720</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">1.09</td>
<td align="char" char="–" colspan="1" rowspan="1">0.87–1.36</td>
<td align="char" char="." colspan="1" rowspan="1">0.440</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Extrapyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">1.22</td>
<td align="char" char="–" colspan="1" rowspan="1">0.98–1.51</td>
<td align="char" char="." colspan="1" rowspan="1">0.078</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychiatric symptoms</td>
<td align="char" char="." colspan="1" rowspan="1">0.99</td>
<td align="char" char="–" colspan="1" rowspan="1">0.81–1.22</td>
<td align="char" char="." colspan="1" rowspan="1">0.950</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Visual disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.18</td>
<td align="char" char="–" colspan="1" rowspan="1">0.93–1.48</td>
<td align="char" char="." colspan="1" rowspan="1">0.170</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="5">Visual disturbance</td>
<td align="left" colspan="1" rowspan="1">Myoclonus</td>
<td align="char" char="." colspan="1" rowspan="1">1.51</td>
<td align="char" char="–" colspan="1" rowspan="1">1.16–1.96</td>
<td align="char" char="." colspan="1" rowspan="1">0.002</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">0.80</td>
<td align="char" char="–" colspan="1" rowspan="1">0.61–1.05</td>
<td align="char" char="." colspan="1" rowspan="1">0.110</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Extrapyramidal dysfunction</td>
<td align="char" char="." colspan="1" rowspan="1">0.80</td>
<td align="char" char="–" colspan="1" rowspan="1">0.61–1.05</td>
<td align="char" char="." colspan="1" rowspan="1">0.110</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychiatric symptoms</td>
<td align="char" char="." colspan="1" rowspan="1">1.12</td>
<td align="char" char="–" colspan="1" rowspan="1">0.89–1.41</td>
<td align="char" char="." colspan="1" rowspan="1">0.340</td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cerebellar disturbance</td>
<td align="char" char="." colspan="1" rowspan="1">1.28</td>
<td align="char" char="–" colspan="1" rowspan="1">1.01–1.64</td>
<td align="char" char="." colspan="1" rowspan="1">0.044</td>
<td align="char" char="." colspan="1" rowspan="1">1.28</td>
<td align="char" char="–" colspan="1" rowspan="1">1.01–1.64</td>
<td align="char" char="." colspan="1" rowspan="1">0.044</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="ene13057-note-0003">
<p>Abbreviations as used in Tables <xref ref-type="table-wrap" rid="ene13057-tbl-0001">1</xref> and <xref ref-type="table-wrap" rid="ene13057-tbl-0002">2</xref>. The reference for estimating HRs of clinical signs and symptoms at diagnosis is absence against presence.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<fig fig-type="Figure" id="ene13057-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Schematic description of regression analysis results showing typical sequences of sign and symptom development. For signs or symptoms A (e.g. cerebellar disturbance) and B (e.g. myoclonus), solid arrows from A to B indicate that the A at diagnosis was identified as a prognostic factor by multivariate regression analyses for the time to onset of B. Dashed arrows from C (e.g. myoclonus) to D (e.g. akinetic mutism) indicate that the C at diagnosis was identified as a potential prognostic factor by univariate regression analyses for the time to onset of D.</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="ENE-23-1455-g003"></graphic>
</fig>
</sec>
</sec>
<sec id="ene13057-sec-0017">
<title>Discussion</title>
<p>The presence of psychiatric symptoms or cerebellar disturbance at sCJD diagnosis was associated with a risk for akinetic mutism. A similar result was obtained from analysis of 717 cases including those with akinetic mutism at the time of diagnosis (data not shown). In contrast, the prognostic factors for death, which are assumed to be similar to those for akinetic mutism, are not consistent across genders or ages of onset <xref ref-type="ref" rid="ene13057-bib-0004">4</xref>. These differences from our study might be explained by the previous study's use of clinical signs or symptoms at diagnosis as covariates in multivariate regression analyses, differences in the baseline data and outcomes examined, and the inclusion of patients with codon 129 type VV. Thus, clinical signs and symptoms at diagnosis were strong prognostic factors in our study and can be used as alternatives to gender and age of onset as predictors of future outcomes. In future studies, clinical signs and symptoms at the time of diagnosis should be used as covariates to predict time to onset of akinetic mutism. Although treatment in the early stage of sCJD is essential, the progression of sCJD is rapid and there is little time for effective treatment. However, it was found that cases without cerebellar disturbance or psychiatric symptoms at diagnosis may have a window for therapy of approximately 0.5–2.0 months. Further studies are required to identify clinical signs or symptoms that are useful in the prediction of prognosis and thereby expand the therapeutic period.</p>
<p>The order of onset of clinical signs and symptoms after sCJD diagnosis is described schematically in Fig. <xref ref-type="fig" rid="ene13057-fig-0003">3</xref>. Previous studies have examined sCJD signs or symptoms regardless of their time of appearance after diagnosis. A better understanding of the clinical course of sCJD may be useful for the selection of therapeutic strategies and planning of supportive care. Future studies are needed to investigate the development of clinical signs and symptoms after disease onset, which is typically indicated by progressive dementia, and to further explore sCJD etiology. Furthermore, if the presence of symptoms before CJD diagnosis is assessed, there is a possibility that a specific constellation of symptoms in the prodromal period before diagnosis may be found.</p>
<p>The presence of cerebellar disturbance at diagnosis increased the risks of akinetic mutism (Table <xref ref-type="table-wrap" rid="ene13057-tbl-0002">2</xref>) and four other clinical signs and symptoms (Table <xref ref-type="table-wrap" rid="ene13057-tbl-0003">3</xref>). Thus, cerebellar disturbance may be a key predictive factor for the clinical course of sCJD. Consistent with this finding, patients with cerebellar disturbance showed survival rates of 55.8% and 29.4% for less than or greater than 10 months after diagnosis, respectively <xref ref-type="ref" rid="ene13057-bib-0019">19</xref>. This finding may be attributable to the transmission speed of PrP from certain brain regions or accumulation of PrP in specific structures.</p>
<p>MM1 and MV1 are the most common subtypes of sCJD, accounting for 60%–70% of all cases <xref ref-type="ref" rid="ene13057-bib-0005">5</xref>, <xref ref-type="ref" rid="ene13057-bib-0006">6</xref>. Our data may be affected by a high prevalence of MM1 and MV1 subtypes. As only a quarter of patients underwent genetic tests in this study, it is unclear whether CJD patients with VV type were included. However, the number of CJD patients with VV type would have been limited, given the sample size and a low rate of VV type in Japan <xref ref-type="ref" rid="ene13057-bib-0020">20</xref>. PSDs, cerebellar disturbance and myoclonus are typically not observed in patients with V108I mutations or the MM2 cortical subtype, which are often categorized as sCJD <xref ref-type="ref" rid="ene13057-bib-0006">6</xref>, <xref ref-type="ref" rid="ene13057-bib-0021">21</xref>, <xref ref-type="ref" rid="ene13057-bib-0022">22</xref>, <xref ref-type="ref" rid="ene13057-bib-0023">23</xref>, <xref ref-type="ref" rid="ene13057-bib-0024">24</xref>, <xref ref-type="ref" rid="ene13057-bib-0025">25</xref>. Thus, because most sCJD patients included in our study experienced cerebellar disturbance or myoclonus, our dataset may consist mainly of patients with the MM1 and MV1 subtypes. Hence, our conclusions may be applicable only to these molecular subtypes of sCJD.</p>
<p>There are several limitations to this study. First, our data did not include information on PrP types or genotypes as prognostic factors for survival, although different genotypes are known to be associated with different symptoms and disease time course. However, it was found that clinical signs and symptoms, which reflect disease progression, can be strong prognostic factors for akinetic mutism even in a cohort presumed to be largely MM1 or MV1. Secondly, our analysis was performed without correcting for missing data. However, akinetic mutism onset typically did not have the same incidence date as other clinical signs and symptoms, and further clinical signs and symptoms would not be observed in cases of akinetic mutism or death. Further, to prevent overestimation of the cumulative incidences of other clinical signs and symptoms, akinetic mutism was used as a competing risk in our calculations. Thirdly, because this was a retrospective analysis, our data did not assess conditions related to akinetic mutism. Akinetic mutism involves severely diminished neurological drive and is diagnosed based on markedly diminished movement and speech; however, some patients with akinetic mutism show involuntary movements or vocalizations, including grunts, myoclonus, dystonia and generalized convulsions <xref ref-type="ref" rid="ene13057-bib-0011">11</xref>, <xref ref-type="ref" rid="ene13057-bib-0014">14</xref>. Thus, future prospective studies applying standardized clinical assessments are needed to validate the predictive factors for akinetic mutism found in our study. Finally, because the autopsy rate in Japan was generally low <xref ref-type="ref" rid="ene13057-bib-0020">20</xref>, diagnostic confirmation was not available for most cases in this study and our data are based on clinical diagnosis, allowing for the absence of pathological confirmation in many cases. Despite these limitations, our findings suggest that clinical signs or symptoms may be used as indicators of sCJD progression.</p>
<p>In conclusion, our study demonstrates that the presence of psychiatric symptoms or cerebellar disturbance at the time of sCJD diagnosis increases the likelihood of future onset of akinetic mutism in sCJD cases with probable MM/MV subtypes. Evidence of temporal relationships between specific sCJD signs and symptoms is also provided.</p>
</sec>
<sec id="ene13057-sec-0019">
<title>Disclosure of conflicts of interest</title>
<p>The authors declare no financial or other conflicts of interest.</p>
</sec>
</body>
<back>
<ack id="ene13057-sec-0018">
<title>Acknowledgements</title>
<p>We thank Professor Gen Sobue of Nagoya University for his useful comments and criticism. This study was supported by grants for Health and Labour Sciences Research from the MHLW and for Research on Measures for Intractable Disease (Prion Disease).</p>
</ack>
<ref-list content-type="cited-references" id="ene13057-bibl-0001">
<title>References</title>
<ref id="ene13057-bib-0001">
<label>1</label>
<mixed-citation id="ene13057-cit-0001" publication-type="journal">
<string-name>
<surname>Nakatani</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>B</given-names>
</string-name>, <italic>et al</italic>
<article-title>Temporal and regional variations in sporadic Creutzfeldt−Jakob disease in Japan, 2001−2010</article-title>. <source/>Epidemiol Infect
<year>2015</year>; <volume>143</volume>: <fpage>1073</fpage>–<lpage>1078</lpage>.<pub-id pub-id-type="pmid">25034354</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0002">
<label>2</label>
<mixed-citation id="ene13057-cit-0002" publication-type="journal">
<string-name>
<surname>Masters</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Gajdusek</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Gibbs</surname>
<given-names>CJ</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Bernoulli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Asher</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Creutzfeldt−Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering</article-title>. <source/>Ann Neurol
<year>1979</year>; <volume>5</volume>: <fpage>177</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">371520</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0003">
<label>3</label>
<mixed-citation id="ene13057-cit-0003" publication-type="journal">
<string-name>
<surname>Ladogana</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Puopolo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Croes</surname>
<given-names>EA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mortality from Creutzfeldt−Jakob disease and related disorders in Europe, Australia, and Canada</article-title>. <source/>Neurology
<year>2005</year>; <volume>64</volume>: <fpage>1586</fpage>–<lpage>1591</lpage>.<pub-id pub-id-type="pmid">15883321</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0004">
<label>4</label>
<mixed-citation id="ene13057-cit-0004" publication-type="journal">
<string-name>
<surname>Pocchiari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Puopolo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Croes</surname>
<given-names>EA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Predictors of survival in sporadic Creutzfeldt−Jakob disease and other human transmissible spongiform encephalopathies</article-title>. <source/>Brain
<year>2004</year>; <volume>127</volume>: <fpage>2348</fpage>–<lpage>2359</lpage>.<pub-id pub-id-type="pmid">15361416</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0005">
<label>5</label>
<mixed-citation id="ene13057-cit-0005" publication-type="journal">
<string-name>
<surname>Gambetti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kong</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zou</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Parchi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>SG</given-names>
</string-name>. <article-title>Sporadic and familial CJD: classification and characterisation</article-title>. <source/>Br Med Bull
<year>2003</year>; <volume>66</volume>: <fpage>213</fpage>–<lpage>239</lpage>.<pub-id pub-id-type="pmid">14522861</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0006">
<label>6</label>
<mixed-citation id="ene13057-cit-0006" publication-type="journal">
<string-name>
<surname>Parchi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Giese</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Capellari</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Classification of sporadic Creutzfeldt−Jakob disease based on molecular and phenotypic analysis of 300 subjects</article-title>. <source/>Ann Neurol
<year>1999</year>; <volume>46</volume>: <fpage>224</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">10443888</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0007">
<label>7</label>
<mixed-citation id="ene13057-cit-0007" publication-type="journal">
<string-name>
<surname>Puopolo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ladogana</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Almonti</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mortality trend from sporadic Creutzfeldt−Jakob disease (CJD) in Italy, 1993−2000</article-title>. <source/>J Clin Epidemiol
<year>2003</year>; <volume>56</volume>: <fpage>494</fpage>–<lpage>499</lpage>.<pub-id pub-id-type="pmid">12812825</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0008">
<label>8</label>
<mixed-citation id="ene13057-cit-0008" publication-type="journal">
<string-name>
<surname>Heinemann</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Krasnianski</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Meissner</surname>
<given-names>B</given-names>
</string-name>, <italic>et al</italic>
<article-title>Creutzfeldt−Jakob disease in Germany: a prospective 12‐year surveillance</article-title>. <source/>Brain
<year>2007</year>; <volume>130</volume>: <fpage>1350</fpage>–<lpage>1359</lpage>.<pub-id pub-id-type="pmid">17472986</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0009">
<label>9</label>
<mixed-citation id="ene13057-cit-0009" publication-type="journal">
<string-name>
<surname>Appleby</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Appleby</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Crain</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Onyike</surname>
<given-names>CU</given-names>
</string-name>, <string-name>
<surname>Wallin</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Rabins</surname>
<given-names>PV</given-names>
</string-name>. <article-title>Characteristics of established and proposed sporadic Creutzfeldt−Jakob disease variants</article-title>. <source/>Arch Neurol
<year>2009</year>; <volume>66</volume>: <fpage>208</fpage>–<lpage>215</lpage>.<pub-id pub-id-type="pmid">19204157</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0010">
<label>10</label>
<mixed-citation id="ene13057-cit-0010" publication-type="journal">
<string-name>
<surname>Parchi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Castellani</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Capellari</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Molecular basis of phenotypic variability in sporadic Creutzfeldt−Jakob disease</article-title>. <source/>Ann Neurol
<year>1996</year>; <volume>39</volume>: <fpage>767</fpage>–<lpage>778</lpage>.<pub-id pub-id-type="pmid">8651649</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0011">
<label>11</label>
<mixed-citation id="ene13057-cit-0011" publication-type="journal">
<string-name>
<surname>Nagoshi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sadakane</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yamada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mizusawa</surname>
<given-names>H</given-names>
</string-name>. <article-title>Duration of prion disease is longer in Japan than in other countries</article-title>. <source/>J Epidemiol
<year>2011</year>; <volume>21</volume>: <fpage>255</fpage>–<lpage>262</lpage>.<pub-id pub-id-type="pmid">21628843</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0012">
<label>12</label>
<mixed-citation id="ene13057-cit-0012" publication-type="journal">
<string-name>
<surname>Iwasaki</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mimuro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kitamoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hashizume</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Survival to akinetic mutism state in Japanese cases of MM1‐type sporadic Creutzfeldt−Jakob disease is similar to Caucasians</article-title>. <source/>Eur J Neurol
<year>2011</year>; <volume>18</volume>: <fpage>999</fpage>–<lpage>1002</lpage>.<pub-id pub-id-type="pmid">20722706</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0013">
<label>13</label>
<mixed-citation id="ene13057-cit-0013" publication-type="journal">
<string-name>
<surname>Iwasaki</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tatsumi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mimuro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kitamoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>M</given-names>
</string-name>. <article-title>Comparison of the clinical course of Japanese MM1‐type sporadic Creutzfeldt−Jakob disease between subacute spongiform encephalopathy and panencephalopathic‐type</article-title>. <source/>Clin Neurol Neurosurg
<year>2014</year>; <volume>121</volume>: <fpage>59</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">24793477</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0014">
<label>14</label>
<mixed-citation id="ene13057-cit-0014" publication-type="journal">
<string-name>
<surname>Iwasaki</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hashizume</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kitamoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sobue</surname>
<given-names>G</given-names>
</string-name>. <article-title>Clinicopathologic characteristics of sporadic Japanese Creutzfeldt−Jakob disease classified according to prion protein gene polymorphism and prion protein type</article-title>. <source/>Acta Neuropathol
<year>2006</year>; <volume>112</volume>: <fpage>561</fpage>–<lpage>571</lpage>.<pub-id pub-id-type="pmid">16847689</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0015">
<label>15</label>
<mixed-citation id="ene13057-cit-0015" publication-type="journal">
<string-name>
<surname>Hayashi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Umeda</surname>
<given-names>T</given-names>
</string-name>. <article-title>35 years of Japanese policy on rare diseases</article-title>. <source/>Lancet
<year>2008</year>; <volume>372</volume>: <fpage>889</fpage>–<lpage>890</lpage>.<pub-id pub-id-type="pmid">18790305</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0016">
<label>16</label>
<mixed-citation id="ene13057-cit-0016" publication-type="miscellaneous">
<article-title>Japan Intractable Diseases Information Center</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.nanbyou.or.jp/english/nan_kenkyu_45.htm">http://www.nanbyou.or.jp/english/nan_kenkyu_45.htm</ext-link> (accessed 6/29/2014).</mixed-citation>
</ref>
<ref id="ene13057-bib-0017">
<label>17</label>
<mixed-citation id="ene13057-cit-0017" publication-type="journal">
<string-name>
<surname>Gooley</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Leisenring</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Crowley</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Storer</surname>
<given-names>BE</given-names>
</string-name>. <article-title>Estimation of failure probabilities in the presence of competing risks: new representations of old estimators</article-title>. <source/>Stat Med
<year>1999</year>; <volume>18</volume>: <fpage>695</fpage>–<lpage>706</lpage>.<pub-id pub-id-type="pmid">10204198</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0018">
<label>18</label>
<mixed-citation id="ene13057-cit-0018" publication-type="journal">
<string-name>
<surname>Fine</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Gray</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>A proportional hazards model for the subdistribution of a competing risk</article-title>. <source/>J Am Stat Assoc
<year>1999</year>; <volume>94</volume>: <fpage>496</fpage>–<lpage>509</lpage>.</mixed-citation>
</ref>
<ref id="ene13057-bib-0019">
<label>19</label>
<mixed-citation id="ene13057-cit-0019" publication-type="journal">
<string-name>
<surname>Appleby</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Appleby</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Rabins</surname>
<given-names>PV</given-names>
</string-name>. <article-title>Does the presentation of Creutzfeldt−Jakob disease vary by age or presumed etiology? A meta‐analysis of the past 10 years</article-title>. <source/>J Neuropsychiatry Clin Neurosci
<year>2007</year>; <volume>19</volume>: <fpage>428</fpage>–<lpage>435</lpage>.<pub-id pub-id-type="pmid">18070846</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0020">
<label>20</label>
<mixed-citation id="ene13057-cit-0020" publication-type="journal">
<string-name>
<surname>Nozaki</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hamaguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sanjo</surname>
<given-names>N</given-names>
</string-name>, <italic>et al</italic>
<article-title>Prospective 10‐year surveillance of human prion diseases in Japan</article-title>. <source/>Brain
<year>2010</year>; <volume>133</volume>: <fpage>3043</fpage>–<lpage>3057</lpage>.<pub-id pub-id-type="pmid">20855418</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0021">
<label>21</label>
<mixed-citation id="ene13057-cit-0021" publication-type="journal">
<string-name>
<surname>Jin</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shiga</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shibuya</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Clinical features of Creutzfeldt−Jakob disease with V180I mutation</article-title>. <source/>Neurology
<year>2004</year>; <volume>62</volume>: <fpage>502</fpage>–<lpage>505</lpage>.<pub-id pub-id-type="pmid">14872044</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0022">
<label>22</label>
<mixed-citation id="ene13057-cit-0022" publication-type="journal">
<string-name>
<surname>Hamaguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kitamoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Clinical diagnosis of MM2‐type sporadic Creutzfeldt−Jakob disease</article-title>. <source/>Neurology
<year>2005</year>; <volume>64</volume>: <fpage>643</fpage>–<lpage>648</lpage>.<pub-id pub-id-type="pmid">15728285</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0023">
<label>23</label>
<mixed-citation id="ene13057-cit-0023" publication-type="journal">
<string-name>
<surname>Mastrianni</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Nixon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Layzer</surname>
<given-names>R</given-names>
</string-name>, <italic>et al</italic>
<article-title>Prion protein conformation in a patient with sporadic fatal insomnia</article-title>. <source/>N Engl J Med
<year>1999</year>; <volume>340</volume>: <fpage>1630</fpage>–<lpage>1638</lpage>.<pub-id pub-id-type="pmid">10341275</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0024">
<label>24</label>
<mixed-citation id="ene13057-cit-0024" publication-type="journal">
<string-name>
<surname>Parchi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Capellari</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chin</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>A subtype of sporadic prion disease mimicking fatal familial insomnia</article-title>. <source/>Neurology
<year>1999</year>; <volume>52</volume>: <fpage>1757</fpage>–<lpage>1763</lpage>.<pub-id pub-id-type="pmid">10371520</pub-id></mixed-citation>
</ref>
<ref id="ene13057-bib-0025">
<label>25</label>
<mixed-citation id="ene13057-cit-0025" publication-type="journal">
<string-name>
<surname>Yamashita</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nishinaka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Udaka</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kameyama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kitamoto</surname>
<given-names>T</given-names>
</string-name>. <article-title>Severe brain atrophy in a case of thalamic variant of sporadic CJD with plaque‐like PrP deposition</article-title>. <source/>Neuropathology
<year>2001</year>; <volume>21</volume>: <fpage>138</fpage>–<lpage>143</lpage>.<pub-id pub-id-type="pmid">11396679</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>